Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adiposity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    124 result(s) found for: Adiposity. Displaying page 4 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2005-002364-29 Sponsor Protocol Number: 015 Start Date*: 2005-09-02
    Sponsor Name:
    Full Title: A Two Year Study to Assess the Efficacy, Safety, and Tolerability of MK-0364 in Obese Patients
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NO (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002454-21 Sponsor Protocol Number: 014 Start Date*: 2005-08-19
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK-0364) in Obese Patients Followed by a 1-Year Ext...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    7.1 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) IE (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005192-18 Sponsor Protocol Number: A5351022 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Ltd.
    Full Title: A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABET...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) SK (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002199-88 Sponsor Protocol Number: NN8022-1922 Start Date*: 2008-12-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes A 56 week randomised, double-blind, placebocontrolled, three armed parallel group, multi-centre, multina...
    Medical condition: Obesity and overweight
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    14.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002479-37 Sponsor Protocol Number: 1404-0036 Start Date*: 2021-03-15
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: A Phase II, randomized, double blind, parallel group,46 weeks dose-finding study of BI 456906 administered once weekly subcutaneously compared with placebo in patients with obesity or overweight
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Prematurely Ended) NL (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006175-36 Sponsor Protocol Number: R256918OBE1008 Start Date*: 2008-02-13
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000546-34 Sponsor Protocol Number: NN8022-4392 Start Date*: 2021-02-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PT (Trial now transitioned) NO (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2021-001247-27 Sponsor Protocol Number: 202100166 Start Date*: 2021-09-30
    Sponsor Name:University Medical Center Groningen
    Full Title: SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetes
    Medical condition: Overweight and obese individuals at high risk of chronic kidney disease progression.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002939-29 Sponsor Protocol Number: NN9536-4734 Start Date*: 2021-07-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of subcutaneous semaglutide 2.4 mg once-weekly in subjects with obesity and prediabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-003380-35 Sponsor Protocol Number: EX9536-4388 Start Date*: 2018-10-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
    Medical condition: Overweight Obesity
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DK (Completed) FI (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) LV (Completed) NL (Completed) CZ (Completed) HU (Completed) BE (Completed) AT (Completed) SE (Completed) HR (Completed) NO (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-000790-94 Sponsor Protocol Number: NN9536-4999 Start Date*: 2022-11-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity.
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) PT (Completed) NO (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000703-15 Sponsor Protocol Number: A5351028 Start Date*: 2007-06-19
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, United States
    Full Title: A 15 MONTH, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF CP 945,598 IN PREVENTION OF WEIGHT REGAIN IN OBESE SUBJECTS
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003616-39 Sponsor Protocol Number: 64565111OBE2001 Start Date*: 2018-04-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic S...
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002422-78 Sponsor Protocol Number: 1 Start Date*: 2013-10-14
    Sponsor Name:University of Leicester
    Full Title: Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial.
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002076-41 Sponsor Protocol Number: 0667 Start Date*: 2018-08-23
    Sponsor Name:University of Leicester
    Full Title: A RANDOMISED CONTROLLED TRIAL OF PRE-SURGERY SODIUM VALPROATE, FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: Val-CARD
    Medical condition: Reduction of myocardial and kidney injury risk of post cardiac surgery by increasing the expression of genes that promote myocardial mitochondrial homeostasis via effects on chromatin histone deace...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    20.1 100000004849 10057768 Post-cardiac injury syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-004988-42 Sponsor Protocol Number: 12DIAB15 Start Date*: 2013-02-05
    Sponsor Name:Sandwell and West Birmingham Hospitals NHS Trust
    Full Title: REVISE-Diabesity: Randomisation to Endoluminal intestinal liner alone Versus with Incretin analogue in SustainEd Diabesity
    Medical condition: Combined Type 2 diabetes mellitus and obesity.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-000060-34 Sponsor Protocol Number: LOCAL/2015/APM-01 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Nîmes
    Full Title: Effets vasculaires et métaboliques d'une supplémentation en Vitamine D associée à une prise en charge hygiéno-diététique chez l'Adolescent Obèse: étude prospective, randomisée, contrôlée
    Medical condition: Obésité chez l'adolescent
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001145-93 Sponsor Protocol Number: 69HCL15_0057 Start Date*: 2015-10-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Étude pharmacocinétique de la lidocaïne par voie intraveineuse en chirurgie bariatrique - Etude SPIRAL (Safety Profile of IntRAvenous Lidocaïne use in coelioscopic bariatric surgery)
    Medical condition: Obésité / Chirurgie bariatrique
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10068900 Bariatric surgery LLT
    18.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016663-11 Sponsor Protocol Number: ORA111850 Start Date*: 2010-08-27
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour...
    Medical condition: GSK1521498 is a novel opioid receptor inverse agonist that is being developed for the treatment of obesity.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022815-21 Sponsor Protocol Number: FARM87JEA3 Start Date*: 2010-12-16
    Sponsor Name:UNIVERSITA` DI TORINO
    Full Title: Use of metformin in obese adolescent patients
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027433 SOC
    9.1 10003018 HLGT
    9.1 10018067 HLT
    9.1 10029883 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 20:25:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA